IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR IR HOME NEWS & EVENTS OVERVIEW PRESS RELEASES EVENTS & PRESENTATIONS STOCK INFORMATION OVERVIEW HISTORIC STOCK LOOKUP INVESTMENT CALCULATOR ANALYST COVERAGE FINANCIALS & FILINGS OVERVIEW SEC FILINGS CORPORATE GOVERNANCE OVERVIEW LEADERSHIP BOARD OF DIRECTORS COMMITTEE COMPOSITION CONTACT IR Ardelyx to Present at the Jefferies 2023 Healthcare Conference Read more about Ardelyx to Present at the Jefferies 2023 Healthcare Conference Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor) Read more about Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor) Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults Read more about Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update Read more about Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference Read more about Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023 Read more about Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023 Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor) Read more about Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor) Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to FAQs Email Alerts Connect
Ardelyx to Present at the Jefferies 2023 Healthcare Conference Read more about Ardelyx to Present at the Jefferies 2023 Healthcare Conference
Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor) Read more about Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults Read more about Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update Read more about Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference Read more about Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023 Read more about Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor) Read more about Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
Ardelyx, Inc. Reports Employment Inducement Grants Read more about Ardelyx, Inc. Reports Employment Inducement Grants